Upfront ICIs May Enhance Second-Line Responses in NSCLC ...Middle East

Medscape - News
Second-line ramucirumab and docetaxel after use of immune checkpoint inhibitors may improve some outcomes for patients with NSCLC. The study was published as a preprint and has not yet been peer reviewed. First Look

Hence then, the article about upfront icis may enhance second line responses in nsclc was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Upfront ICIs May Enhance Second-Line Responses in NSCLC )

Apple Storegoogle play

Last updated :

Also on site :



Latest News